EU Approves Agilent's Keytruda Companion Diagnostic for Ovarian Cancer
A sits 26% above its 52-week low of $108.35.
Summary
Agilent received EU certification for its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic for Keytruda in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. This is the eighth CE-marked indication for the test, expanding its addressable market in Europe. The approval follows the FDA's expanded clearance for esophageal cancer in June, showing continued regulatory momentum for the diagnostics portfolio. While the financial impact is modest relative to Agilent's $6.95B revenue base, each new indication strengthens the recurring revenue stream from companion diagnostics and reinforces the partnership with Merck. The test aids in identifying patients for Keytruda in the platinum-resistant setting, where treatment options are limited.
At the time of this announcement, A was trading at $137.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $37.7B. The 52-week trading range was $108.35 to $160.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.